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Abstract
Mitophagy is a selective form of autophagy that eliminates mitochondria and is part of
a larger network of mitochondrial quality control processes that respond to mitochon‐
drial  damage.  Treatment of  haematological  malignancies often involves drugs that
ultimately cause cell death by mitochondrial injury and initiation of apoptosis. Thus,
mitophagy  is  a  potential  cause  of  resistance  to  anticancer  drugs  that  target  the
mitochondria (mitocans). Since mitophagy is integrated to mitochondrial biogenesis,
mitochondrial fission and fusion, the bioenergetics profile and metabolic reprogram‐
ming of tumour cells, the blockage of mitophagy may not be sufficient to overcome
resistance. In addition, the mitochondrial unfolded protein response and the outer
mitochondrial  membrane‐associated  degradation  have  extensive  crosstalk  with
mitophagy, and advanced forms of neoplasms will  require targeting both systems.
Proteasome inhibitors and vinca alkaloids target many of the critical steps involved in
resistance  to  mitocans,  while  inducers  of  mitochondrial  turnover  (biogenesis  and
mitophagy) like valproic acid have a variable effect depending on metabolic reprog‐
raming and the activity of oxidative phosphorylation of tumour cells. Here we discuss
the mechanisms of mitophagy and its associated mechanisms, and discuss its applica‐
tion to the rationale of  targeted combined therapies of  low‐ and high‐grade B‐cell
neoplasms.
Keywords: mitocans, arsenic trioxide, BNIP3, Parkin, aggresome, Proteasome inhibi‐
tors, valproic acid, vincristine, mitochondrial dynamics, mitochondrial turnover, met‐
abolic reprogramming, lymphoma, myeloma, chronic lymphocytic leukemia (CLL)
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1. Introduction
Autophagy is a cell response that aims to recycle proteins, cytoplasmic components and even
organelles particularly under starvation conditions [1]. Mitochondria are one of the many
organelles and cytoplasmic components that can be identified as the cargo within autopha‐
gosomes. More recently, this kind of autophagy has been referred to as bulk or non‐selective
autophagy, to underscore that there is no particular selection of the cellular components that
may enter the autophagy process.  The main driver of nutrient depletion autophagy is a
catabolic response to provide amino acids and support metabolic pathways such as gluco‐
neogenesis and ketogenesis. By contrast, mitophagy is defined as the selective autophagy of
mitochondria [2].  In fact,  elimination of mitochondria is  particularly avoided in nutrient
depletion autophagy. Since mitochondria is the source of ATP in normoxia, supports lipid
biosynthesis, gluconeogenesis, ketogenesis and many other metabolic functions that take place
precisely under nutrient depletion, mitochondria are spare as much as possible under catabolic
conditions [3].  One of the first metabolic contexts where mitochondria were found to be
eliminated with selectivity was hypoxia. Even under normal nutrient conditions, cells exposed
to  hypoxia  will  undergo increased oxidative  stress.  The  absence  of  O2  causes  abnormal
function of the electron transport chain (ETC) and oxidative phosphorylation (OXPHOS), and
this leads to increased superoxide anion leakage and reactive oxygen species (ROS) production
[4]. The main driver of response to hypoxia is the increase in mitochondrial ROS, which
stabilizes the hypoxia inducing factor 1α (HIF‐1α) by preventing its proteasome degradation.
HIF‐1α is a transcription factor that orchestrates an array of changes in mitochondrial proteins
to  reduce  OXPHOS  and  particularly  promotes  mitophagy  resulting  in  the  reduction  of
mitochondrial  mass.  Nevertheless,  mitophagy  may  occur  under  many  other  conditions
leading to abnormal function of mitochondria, particularly if it involves increased mitochon‐
drial  ROS  (mtROS).  Increased  mtROS  can  lead  to  collapse  of  mitochondrial  membrane
potential  (MMP),  mitochondrial  outer  membrane  permeabilization  (MOMP),  release  of
cytochrome c and initiation of intrinsic apoptosis. However, elimination of mitochondria by
mitophagy prior to MOMP may prevent apoptosis particularly if the production of mtROS is
not massive.
We review how mitophagy is integrated to mitochondrial quality control (QC), mitochon‐
drial turnover and mitochondrial dynamics, and we discuss the interdependency with the
bioenergetics profile of the cell. This knowledge will be further considered to discuss its im‐
plication in resistance to treatment of haematological malignancies, and how combined
therapies can be selected to target mitophagy, mitochondrial biogenesis and compensating
mechanisms of resistance that involve the ubiquitin proteasome system (UPS), particularly
in the most aggressive forms of lymphomas. We discuss the use of drugs already in clinical
use that may be potentially combined based on their recognized effects on mitophagy, au‐
tophagy and mitochondrial biogenesis. We finally discuss methods that can help determine
the status of resistance mechanisms based on mitophagy in lymphoma cells obtained from
patients.
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2. Mitophagy and mitochondrial turnover
2.1. Mitophagy is coupled to biogenesis and both occur at perinuclear areas
Mitochondria are far from being static and frequently change their shape and size. Even in a
single cell they are not equal to one another, a condition called heteroplasmy, and there is still
a great variation depending on the cell type. Recently the term “mitochondrial behaviour” was
proposed to embrace all these properties and states, underscoring the need to integrate the
many dimensions of mitochondrial study [5]. Mitochondria spread around the cell by attaching
to the microtubule network and move to the areas of high energy demands to provide
OXPHOS‐derived ATP. Even though mitophagy reduces the mitochondrial mass, this process
is coupled to mitochondrial biogenesis through a homeostatic loop, in order to keep the
mitochondrial mass in accordance with the bioenergetics demands of the cell [6]. Mitochon‐
drial biogenesis requires duplication of mitochondrial DNA (mtDNA), the expression of new
mtDNA‐coded proteins, nuclear DNA‐coded mitochondrial proteins and a huge work of
mitochondrial protein import. This process is controlled by the peroxisome proliferator‐
activated receptor gamma coactivator 1‐alpha (PGC‐1α) transcription factor that regulates the
expression of a large number of nuclear‐encoded mitochondrial genes. Biogenesis involves
elongation of existing mitochondria and further fission of the newly formed units (Figure 1).
In fact, what is known as a mitochondrion may contain several units, each one with a single
copy of mtDNA forming a nucleoid, and a completely assembled respiratory chain complex.
Remarkably, the process of elongation and protein import associated with biogenesis occurs
in perinuclear mitochondria [7]. The induction of biogenesis after mitophagy is often referred
as the nuclear retrograde response, and is an important regulator of mitochondrial turnover
because it leads to changes in the grade of heteroplasmy of the entire mitochondrial network.
In cases of mutated mtDNA the grade of heteroplasmy may be critical for the severity of
mitochondrial damage or malfunction.
2.2. Mitophagy is initiated after mitochondrial fission
Mitochondrial biogenesis involves elongation and fission, but fission also occurs apart from
biogenesis [8]. In fact, mitochondria may be divided at positions dictated by a surrounding
endoplasmic reticulum (ER) that corresponds to the joint between internal units. These sites
are known as sites of ER‐associated mitochondrial division (ERMD) [9]. At these sites dynamin
relates protein 1 (DRP1) is recruited to constrict and further split mitochondria during fission
(Figure 1). Fission allows the segregation of individual units with impaired or abnormal
function that can no longer sustain a normal OXPHOS, the MMP, and the production of ATP
[10]. Mitochondria with otherwise normal function can fuse again by the activation of Mfn1
and Mfn2, which accomplish fusion of the outer mitochondrial membrane (OMM), and OPA1
that completes fusion of internal mitochondrial membrane (IMM) [5]. In contrast, segregated
mitochondria with abnormal function can no longer fuse again due to inactivation of Mfn1
and OPA1 particularly due to collapsed MMP. Thus, fission and segregation of mitochondria
with collapsed MMP is the first step in the process of mitophagy (Figure 1) [10]. During
mitophagy, the tip‐ends of split mitochondria are kept sufficiently closed to prevent MOMP
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and cytochrome c release [11]. However, the particular phospholipid cardiolipin (CL), which
is normally concentrated in the IMM, is partially exposed at the OMM. CL at the OMM acts
as an “eat me” signal to initiate mitophagy, much in the same way as phophatidylserine acts
as an “eat me” signal in the cell membrane during apoptosis [12]. The collapse of MMP acts to
stabilize Pink1 and recruits the E3 ubiquitin ligase Parkin, while further attachment of p62 at
the OMM initiates the formation of the mitophagosome [13]. In contrast to mitophagy, during
intrinsic apoptosis the entire mitochondrial network undergoes fission, and at these tip‐ends
occurs a massive oxidation of CL that leads to MOMP, cytochrome c oxidation and further
release to the cytosol.
Figure 1. Transitional states of mitochondria.
Mitochondria undergo rounds of fusion and fission. Mitophagy is initiated after fission as part
of mitochondrial quality control. Fission involves Drp1, while fusion requires Mfn1, Mfn2 and
OPA1. Parkin and BNIP3 are the two most common mitophagy receptors. Mitophagy is
coupled to biogenesis through the retrograde nuclear signalling. Mitochondrial biogenesis is
initiated by mtDNA duplication and elongation, with assembly of a completely new nucleoid
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and respiratory unit. The elongated mitochondria start undergoing fission ad fusion. Mitocans
are anticancer drugs that target the mitochondria and induce intrinsic apoptosis after inflicting
different sorts of mitochondrial damage. Mitophagy can counterbalance this damage by
removing compromised mitochondria; while mitochondrial biogenesis completes a turnover
cycle by maintaining mitochondrial mass. Valproic acid (VPA) induces mitophagy by upre‐
gulation of BNIP3 and mitochondrial biogenesis by upregulating PGC‐1α.
2.3. Bioenergetics implications of mitochondrial fusion and fission-metabolic
reprogramming
Mitophagy and mitochondrial biogenesis do not provide a complete picture of the regulation
of mitochondrial network, unless it is integrated to the metabolic changes associated with
mitochondrial dynamics, which is a term that is used to refer collectively to mitochondrial
fusion and fission. A hyperfused network in normoxia often denotes a high respiratory rate
with high OXPHOS activity, O2 consumption, ATP production, high MMP and increased
mitochondrial mass. The cycles of fission and fusion contribute to exchange mitochondrial
components, dilute any defects and improve efficiency of respiration. In contrast, a network
with a predominance of fission is often indicative of low OXPHOS‐derived ATP, low O2
consumption, high glycolysis rate and decreased mitochondrial mass, with low exchange of
mitochondrial components. Metabolic reprogramming is a characteristic of cancer cells that
enhances their ability to survive under adverse conditions such as hypoxia and nutrient
deprivation [14]. Cancer cells may use either glycolysis or OXPHOS as a source of ATP, and
these two alternatives may be not mutually exclusive, and can vary during the progression of
the disease depending on several factors. OXPHOS redirection towards lipid and protein
synthesis, truncation of Krebs’s cycle and glycolysis can all be regulated to support tumour
growth, meeting particular demands that appear under harsh growing conditions, such as
glucose and other nutrients deprivation, lack of oxygen and the expression of particular
oncogenes [15]. The oncogene c‐MYC, which is characteristically overexpressed in high‐grade
Burkitt´s lymphoma, participates in this regulation through the expression of genes required
for either OXPHOS or glycolysis [15]. We will next consider a heterogeneous group of B‐cell
lymphomas as an example to discuss the role of mitophagy in disease progression and
response to treatment with a particular emphasis on metabolic reprogramming.
2.4. Metabolic features of low- and high-grade lymphomas
Mature B‐cell neoplasms are broadly classified as low‐grade (indolent) and high‐grade
(aggressive) considering the severity of symptoms, rate of progression and response to
treatment [16]. The most frequent low‐grade B‐cell neoplasm is chronic lymphocytic leukaemia
(CLL) also denoted as small lymphocytic lymphoma. Among high‐grade B‐cell lymphomas,
the most frequent ones are diffuse large B cell lymphoma (DLBCL) and Burkitt´s lymphoma.
CLL is a small cell lymphoma with a large number of non‐dividing mature B‐cells circulating
in the peripheral blood. These B‐cells may enter the lymph nodes where they can survive under
a hypoxic environment (hypoxic niche), receive growth signals and replicate in a location often
protected from the effect of anticancer drugs. However, CLL cells circulating in the peripheral
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blood show activated HIF‐1α, even though they are exposed to normoxic conditions. Progres‐
sion of CLL often leads to a transformation into high‐grade lymphomas such as DLBCL, a
process designated as Ritcher´s transformation [17]. Metabolic reprogramming parallels to
some extent the grading and aggressiveness of these lymphomas [18]. In one extreme, CLL
cells appear as small mature lymphocytes with metabolic features much similar to normal B‐
cells. This includes an efficient use of OXPHOS, low rates of glycolysis with a peripheral
arrangement of predominantly fused mitochondria. By contrast, high‐grade lymphoma cells
appear as large immature cells with very high rates of glycolysis, low use of O2 and OXPHOS,
high production of lactic acid and an extensive use of glucose and glutamine. High‐grade
lymphomas may show high rates of mitophagy and autophagy with a network distribution
that is often more perinuclear than peripheral [19]. When metabolically reprogrammed cells
do not derive ATP from OXPHOS, they are less vulnerable to mtROS under hypoxia.
2.5. Mitophagy and metabolic reprogramming cause resistance to mitocans
Mitocans are a heterogeneous group of anticancer drugs that target the mitochondria and
initiate apoptosis [20]. Mitocans may enhance OXPHOS (hexoquinase II blockers, sodium
dichloroacetate, 2‐bromopyruvate), block the ETC (tamoxifen, adaphostin), oxidize thiol
groups and deplete mitochondrial glutathione (arsenic trioxide) or destabilize VDAC.
Eventually, mitocans increase mtROS and initiate apoptosis by inducing MOMP. Mitocans like
arsenic trioxide (ATO) are used to treat promyelocytic leukaemia but other haematological
malignancies are often resistant [21]. ATO targets the ETC and oxidizes thiol groups by
increasing mtROS. Metabolic reprogramming and mitophagy can have a great influence in
resistance to the induction of apoptosis by ATO or other mitocans. In low‐grade lymphomas
mitocans like ATO that target the ETC and alter OXPHOS, induce massive mtROS and trigger
apoptosis. However, the cytotoxicity of ATO is significantly reduced in high‐grade lymphomas
because of their low OXPHOS‐dependency and high rates of mitophagy with increased
mitochondrial turnover [19]. ATO as other mitocans can hardly inflict mitochondrial damage
in these OXPHOS‐independent cells, and in addition, damaged mitochondria are effectively
replaced by a high mitochondrial turnover. A high rate of mitochondrial biogenesis is also
required to assist rapid proliferation, which is a characteristic feature of these high‐grade
lymphoma cells.
2.6. Transport of mitophagosomes over the microtubule network
Mitophagy is initiated after fission and segregation of mitochondria with collapsed MMP. The
first step involves the role of the E3 ubiquitin ligase Parkin [13]. Many proteins of OMM become
ubiquitinated by Parkin. Among these Mfn1, Mfn2, Miro and Paris help to highlight the
interaction of mitophagy with mitochondrial turnover and dynamics. Ubiquitination of Mfn1
precludes further fusion, ubiquitination of Miro immobilizes mitochondria and fixes it to the
microtubule network, and ubiquitination of Paris causes an increase in the expression of
PGC‐1α, initiating the nuclear retrograde signalling that leads to biogenesis [22, 23]. Interest‐
ingly, Parkin is able to carry on K48 and K63 linked polyubiquitination, but recent studies
support a preferential K63, K11 and K6 links for Parkin [24]. While K48 is a polyubiquitin
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modification known to target proteasome degradation, K63‐linked polyubiquitin has been
more specifically related to mitophagy, and even the mitochondrial deubiquitinase (DUB)
USP30 was shown to block Parkin‐mediated mitophagy by selectively eliminating this kind of
polyubiquitins [25]. The ubiquitination of OMM proteins recruits p62, a linker molecule that
has a ubiquitin binding domain (UBD) and a LC3 interaction region (LIR) domain, and recruits
LC3 to initiate the formation of the mitophagosome by sequestering the ubiquitinated
organelle (Figure 2) [26]. This initial phase has extensive opportunities for crosstalk between
the UPS and mitophagy. A mitophagy receptor is defined as a molecule that is shuttled to the
OMM, where it interacts with LC3 or gamma‐aminobutyric acid receptor‐associated protein
(GABARAP) to initiate the mitophagosome formation [27]. BNIP3 and NIX are two mitophagy
receptors that respond to increase in mtROS by inserting into the OMM [28]. These BH3‐only
molecules of the Bcl2 family have an LIR domain to initiate the formation of the LC3‐decorated
mitophagosome, even in the absence of p62 (Figure 2). BNIP3 can even cause the recruitment
of Parkin to the OMM facilitating also the p62‐dependent mitophagy pathway. Nix in particular
is responsible for mitophagy during the normal maturation of erythrocytes [29]. The matura‐
tion of mitophagosomes ultimately leads to the fusion with lysosomes. This requires the
transport of mitophagosomes along the microtubule network and is critical to complete the
mitophagy process. The encounter of mitophagosomes and lysosomes often occurs at the
perinuclear area at the minus end of the microtubule network. This is often quite evident in
high‐grade lymphoma cells as well as other aggressive tumour cells. In fact, the term mito‐
aggresome has been used to describe the occurrence of this end stage of mitophagy at the
perinuclear area [30]. Mitochondrial elongation and biogenesis occur in mitochondria located
at the perinuclear area. Thus, mitophagy and the nuclear retrograde response appear to occur
at perinuclear location, having significance to interpret the occurrence of perinuclear mito‐
chondrial clusters (PNMC) in high‐grade B‐cell neoplasms as suggestive of high basal
mitochondrial turnover [19].
2.7. Mitophagy and the mitochondrial unfolded protein response (mtUPR)
The term aggresome is used to describe aggregates of ubiquitinated proteins located at
perinuclear areas. These perinuclear areas close to the microtubule organizing centre (MTOC)
are enriched with proteasomes and function as proteolytic centres. Aggresomes are formed
when these proteolytic centres are no longer able to cope with an overload of misfolded
ubiquitinated proteins [31, 32]. The transport of ubiquitinated proteins to the proteolytic
centres depends on dynein motor‐proteins that move along the microtubule network towards
the minus end at the MTOC. Elimination of misfolded proteins and aggresome formation are
part of the unfolded protein response (UPR) that occurs upon ER‐stress [33]. Impaired
proteolysis by inhibition of proteasomes increases the occurrence of aggresomes. Once
aggresomes are formed, they cannot be cleared by proteasomes and in fact, persistence of
aggresomes leads to proteasome inhibition and apoptosis. However, aggresomes may be
cleared by autophagy. This involves a modification of K48‐linked polyubiquitination to K63‐
linked polyubiquitination and involves the histone deacetylase HDAC6 [34]. Mitochondria
have their own protein QC system that includes the proteases Lon and ClpX in the matrix, and
i‐AAA in the inter‐membrane space. The mitochondrial unfolded protein response (mtUPR)
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is regulated by the transcription factor CHOP and involves upregulation of proteases and
chaperones [35]. When this system is overloaded, misfolded mitochondrial proteins are
exposed at the OMM where they become ubiquitinated and shuttled for proteasome degra‐
dation. Because of the similarity with ER‐associated degradation (ERAD), this mitochondrial
process has recently been designated as OMM‐associated degradation (OMMAD) [2]. This
stress pathway functions as a mitochondrial protein QC independently of mitophagy and may
be similar to the ER‐stress associated UPR, involving K48 ubiquitination of OMM misfolded
proteins [35]. Mitochondrial UPR and mitophagy work in an integrated manner. If the amount
of mitochondrial damage is low, mtUPR and OMMAD may be enough to achieve the required
mitochondrial protein quality control. However, a more severe damage would require
mitophagy as a higher level of mitochondrial quality control leading to recycling of the whole
organelle.
Figure 2. Mitophagy, OMMAD and ERAD require oriented transport through microtubules.
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2.8. The transport to the perinuclear region in UPR and mitophagy
The transport of mitophagosomes and autophagosomes along the microtubule is required for
fusion with lysosomes [36]. In fact, not only mitophagosomes and autophagosomes but also
the entire mitochondrial network moves along microtubules. Mitochondrial biogenesis,
fusion, fission and mitophagy also occur over the microtubule network, and drugs affecting
the microtubule network have a profound impact on all of these processes. Microtubules
metaphorically represent the railways over which cargo‐carrying motor‐proteins move along.
Kinesins are motor‐proteins that carry cargo towards the positive end of microtubules that is
at the cell periphery. In contrast, dyneins carry cargo towards the minus end at the perinuclear
area. In a pioneer study, Lee et al. used nocodazole and overexpression of dynamitin to cause
inhibition of the motor‐protein dynein, and prove that QC mitophagy involved the transport
of mitophagosomes through motor‐proteins towards the perinuclear area, to fuse with
lysosomes at the PNMC (Figure 2) [30]. Even though mitophagy can be blocked very specifi‐
cally by knocking down the motor‐protein dynein, blocking the dynamics of the microtubule
has a profound impact on all motor‐proteins moving along the network. Vincristine, as other
vinca alkaloids, binds to α tubulin and prevents further polymerization, leading to a complete
destabilization of the network. These drugs compromise the entire dynamics of the microtu‐
bule network and have profound impact on all cargo‐carrying motor‐proteins (Figure 2). This
explains why cells are arrested in metaphase during mitosis, but also explains why mitophagy
and UPR are blocked, and why the PNMC and proteolytic centres are disrupted.
The UPR is a protein quality control mechanism that upregulates proteases and chaperones in
response to misfolded and damaged proteins. The OMMAD functions in a similar way as the
ERAD. In ERAD and OMMAD, ubiquitinated proteins are transported through microtubules
to the proteolytic centres where proteasomes are clustered. Similarly, mitophagosomes are
transported to the perinuclear region to fuse with lysosomes. Dynein motor‐proteins transport
cargo towards the minus end close to the microtubule‐organizing centre (MTOC). Vincristine
as other drugs affecting microtubule dynamics block transport and halt ERAD, OMMAD and
mitophagy. Bortezomib may create an overload of toxic misfolded ubiquitinated proteins at
the ER and mitochondria.
2.9. Cancer cells may be addicted to UPR and mitophagy
For several reasons, cancer cells may be adapted to an abnormally high load of misfolded
proteins. One of the best examples is that of multiple myeloma cells [33]. These are malignant
post‐germinal centre B lymphocytes that actively produce and secrete immunoglobulins. Due
to the huge amount of protein synthesis, myeloma cells are liable to ER‐stress and therefore
require activation of the UPR, induction of chaperones and autophagy for survival [37]. A
significant number of genes involved in the UPR are frequently mutated in patients with
multiple myeloma, and the UPR is highly active and increases in advanced disease stages [37].
Multiple myeloma cells may be addicted to the UPR for survival, and drugs that target protein
homeostasis, such as proteasome inhibitors, shift the balance of the UPR from prosurvival to
proapoptotic. However, myeloma cells further evolve alternative mechanisms to deal with ER‐
stress such as autophagy, and the disease remains incurable mainly due to therapy resistance.
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Remarkably, the mitophagy receptor BNIP3 is also upregulated in advanced forms of multiple
myeloma [38]. Most myeloma cells reside in a bone marrow hypoxic niche, and hypoxia
increases ER‐stress and upregulates UPR to deal with an overload of misfolded proteins at the
ER and the mitochondria. Therefore, the UPR and mitophagy may be crucial to avoid the
potential joint toxicity of undegraded misfolded proteins and damaged mitochondria.
2.10. Targeting mitophagy and the UPR with microtubule stabilizing drugs
Several mechanisms of resistance to proteasome inhibitors have been elucidated. The thera‐
peutic targeting of UPS and UPR has similarities to the therapeutic targeting of mitophagy,
and the potential resistance mechanisms may be comparable. Unfolded protein response and
mitophagy are flows that may be potentially toxic after being halted. When proteasome is
inhibited, the halted flow of proteolysis becomes lethal to the cells, due to accumulation of
misfolded proteins. Similarly, when mitophagy is inhibited, the halted flow of elimination of
damaged mitochondria becomes potentially lethal to the cell. However, as discussed before,
mitochondria have an internal protein QC mechanism represented by the mtUPR that involves
chaperones and proteases. In addition, it can target misfolded proteins to the OMM for further
ubiquitination and shuttling to the proteasome (OMMAD). This means that blocking mitoph‐
agy does not warrant an accumulation of potentially lethal organelles that trigger apoptosis.
Remarkably, by destabilizing the microtubule network, both the UPR and mitophagy become
halted. Therefore, the microtubule network is a target where mitophagy, OMMAD and ERAD
are convergent and lead to accumulation of ubiquitinated misfolded proteins and mitochon‐
dria (Figure 2). However, achieving a misfolded protein accumulation capable of causing
mitochondrial toxicity and an increase in ER‐stress, requires the concurrent inhibition of
proteasomes. In a similar way, lethality of mitochondria accumulation depends much on the
quality of mitochondria and factors such as mtROS level. The latter is much influenced by
metabolic reprogramming and the rate of OXPHOS dependency. As commented above,
aggressive neoplasm often have low OXPHOS activity, and damage inflicted to the ETC may
have a low impact in increasing mtROS. This situation accounts for resistance to mitocans and
tolerance to accumulation of damaged mitochondria. However, there are mitocan drugs that
make tumour cells shift to OXPHOS, and thus they can become vulnerable to increased mtROS.
This is the case of 2‐deoxyglucose (2DG) and 3‐bromopyruvate (3BP) that block mitochondrial‐
bound hexokinase and of dichloroacetate (DCA) that blocks pyruvate‐dehydrogenase‐kinase
(PDK) [39]
2.11. The pro-death role of mitophagy receptor BNIP3
BNIP3 is a “BH3‐only member” of the Bcl2 family that was originally described as a pro‐death
molecule that often triggers a caspase‐independent mode of apoptosis. More recently, BNIP3
was also characterized as a mitophagy receptor, and created a controversy about whether it
was a pro‐death or pro‐survival molecule [28]. Supporting its pro‐death role, the knock‐ down
of autophagy genes or the chemical inhibition of autophagy, enhanced apoptosis of cells where
BNIP3 was overexpressed. However, BNIP3 upregulation enhances mitophagy and may help
to eliminate potentially harmful damaged mitochondria [40]. The reconciliation of this dual
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role controversy requires the consideration of mitophagy as a flowing system. If accumulation
of mitochondrial BNIP3 triggers cell death, then the rate of mitophagic flow must be suffi‐
ciently high to eliminate these BNIP3‐bearing mitochondria. Otherwise, if mitophagy is
blocked downstream, the result is that BNIP3 is accumulated at the mitochondria initiating
cell death. In normal cells, BNIP3 is under transcriptional control of HIF‐1α, and the most active
inducer of BNIP3 is hypoxia and the increase of intracellular ROS [41]. BNIP3 targets to
damaged mitochondria particularly under increase of intracellular ROS to initiate mitophagy.
If mitophagic flow is not high enough to eliminate mitochondria, BNIP3 will induce cell death,
otherwise mitophagy eliminates damaged mitochondria contributing to cell survival and
tolerance to hypoxia. Thus, the pro‐death role of BNIP3 is dependent on a balance between
mitochondrial damage and mitophagic flow [19].
2.12. Valproic acid upregulates BNIP3 but also induces mitochondrial biogenesis
Downregulation of BNIP3 may result in failure of tumour cells to undergo cell death, and is
associated with a chemo‐resistant phenotype and decreased patient survival [42]. Samples
from patients with multiple myeloma were found methylated at the BNIP3 promoter, and
methylation was significantly correlated with poor patient survival rates [43]. The finding that
many haematological and other tumour cells have epigenetic silencing of BNIP3, led to the
hypothesis that epigenetic drugs that restore expression of BNIP3 could cause tumour cell
death. In fact, this was confirmed in some kinds of lymphoma, leukaemia and epithelial
tumours. Burkitt´s lymphoma cells have epigenetic silencing of BNIP3 and VPA is a histone
deacetylase (HDAC) inhibitor that upregulates expression of BNIP3. However, upregulation
of VPA improves growth and resistance to death in these cells, and even antagonizes the effect
of mitocans like ATO and improves tolerance to hypoxia [19]. Even though VPA increases the
expression of BNIP3 in high‐grade lymphoma, microarray data from studies conducted in low‐
grade lymphoma cells (CLL) showed that VPA upregulates BNIP3 and many other mitochon‐
dria‐related genes, including PGC‐1α that encodes a master regulator of mitochondrial
biogenesis [44]. Upregulation of PGC1α by VPA was also confirmed in SH‐SY5Y neuroblas‐
toma cells, and even in fibroblasts from patients with mutation in mtDNA polymerase (POLG)
as well as normal controls [45, 46]. Thus, VPA induces mitochondrial biogenesis through
PGC‐1 α and upregulates mitophagy through BNIP3, leading to an increase in mitochondrial
mass and an enhanced mitochondrial turnover [44]. This results in an enhanced metabolic rate
and increased OXPHOS. Patients with POLG mutation are extremely sensitive to VPA toxicity
because, in contrast to normal patients, POLG‐deficient cells cannot tolerate the increased
function of mitochondrial respiratory chain [46]. This exemplifies the fact that defective
mitochondria cannot tolerate increased OXPHOS derived from increased biogenesis. It also
underscores the importance of metabolic reprogramming and the bioenergetics profile of
cancer cells on the outcome of increased mitochondrial biogenesis. Metabolically reprogram‐
med cells of high‐grade lymphomas that have a low rate of OXPHOS and a high rate of
glycolysis can tolerate increased biogenesis. In contrast, low‐grade lymphoma cells that are
OXPHOS‐dependent with low levels of glycolysis will increase OXPHOS upon induction of
mitochondrial biogenesis by drugs like VPA, leading to increased mtROS and apoptosis. This
was confirmed recently in studies conducted in peripheral blood circulating cells obtained
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from CLL patients, where VPA treatment is correlated with the upregulation of several genes
involved in apoptosis [47]. In addition, VPA was synergic with fludarabine on the induction
of apoptosis, and CLL patients treated with VPA plus fludarabine had a better outcome than
patients treated with fludarabine alone. In contrast, the effect of VPA in high‐grade B‐cell
neoplasms such as Burkitt´s lymphoma is quite the opposite, providing survival advantage
even under hypoxia and antagonizing the apoptotic effect of ATO that is a mitocan known to
increase mtROS [19].
2.13. Mitophagy and bioenergetics profile in the cytotoxic response to mitocans
From the above discussion, it is clear that the pro‐death effect of mitocans is dependent on
several interacting factors such as the bioenergetics profile and the induction of increased
mtROS, mitochondrial mass, mitochondrial dynamics and mitophagic flow. VPA influences
many of these factors, but the bioenergetics profile appears critical in determining the sensi‐
tizing or resistance effect in combination with mitocans. The initiation of intrinsic apoptosis
by mitocans demands achieving a critical threshold of damage across the mitochondrial
network. If the mitochondrial damage inflicted by a mitocan is persistent, an increase in
mitochondrial biogenesis may result in an increased amount of damaged mitochondria and
an overload of mitophagic flow. However, mitophagic flow coupled to biogenesis may be high
enough as to keep the cells below the apoptotic threshold. Thus, the efficacy of mitocans will
increase if mitophagic flow is blocked, and conversely the anticancer efficacy of blocking
mitophagy will be enhanced with the addition of mitocans. However, blocking mitophagy
may still leave an overloaded mtUPR, and in the more aggressive forms, the addition of
proteasome inhibitors will contribute to increase damage inflicted by mitocans and blockage
of mitophagy [19]. Finally, mitocans such as 3BMP, 2DG and DCA may sensitize to mtROS
production in OXPHOS‐independent aggressive forms of neoplasms. The induction of
mitochondrial biogenesis and blockage of mitophagy present a certain analogy with thera‐
peutic strategies that induce ER‐stress to create an overload of the UPS, while at the same time
a proteasome inhibitor makes the overload even larger and more toxic. However, in the case
of mitochondria, there is a further need to assure that treatment makes them a real source of
toxicity to the cells, and this involves mitocans and evaluation of the bioenergetics profile of
the target cells.
3. Assessing basal mitophagic flow in lymphoma cells
Lymphoma cells can be obtained from peripheral blood or lymph node biopsies of patients to
be analysed for biological features involved in drug sensitivity, including mitophagic flow and
mitochondrial biogenesis. Mitophagy and biogenesis can be considered in a steady state that
determines the actual mitochondrial mass. As discussed above, this turnover can have a
profound impact on the threshold of mitochondrial damage that initiates apoptosis. This is a
reason why assessing the basal rate of mitophagy provides a first approach to predict sensi‐
tivity to mitocans, and provides a preliminary rationale for combined therapies. Since
mitophagy has to be interpreted as a flow, inhibitors provide an indication of the magnitude
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of this flow. Accumulation of mitochondria occurs after halting mitophagy, while biogenesis
is still active. Thus, the change in mitochondrial mass after halting mitophagy is an indicator
of mitophagic flow [48]. Colocalization between autophagosomes and mitochondria can also
provide an indicator of mitophagy. When mitophagosome formation is blocked upstream,
such as by knocking down ATG genes or using chemical inhibitors of the initiation of autoph‐
agy, colocalization of mitochondria and autophagosomes decreases. By contrast, when
mitophagy is blocked downstream, as for example with vincristine or other inhibitors of
autophagosome‐lysosome fusion, colocalization between autophagosomes and mitochondria
will increase. The morphology and dynamics of the mitochondrial network also provide
interesting information. Since fission is the first step in mitophagy and is required after
elongation during biogenesis, a high rate of basal mitophagy will often show a fragmented
network particularly at the perinuclear area. A fragmented PNMC is characteristic of high rates
of basal mitophagy and biogenesis. The use of vincristine or other microtubule stabilizing
drugs will show a disruption of the PNMC and a transition to a peripheral distribution of the
fragmented network.
3.1. Methods to assess mitochondrial mass and mitophagosomes
Changes of mitochondrial mass can be traced by quantifying mtDNA using QPCR, by
immunochemical methods such as western blot using antibodies directed against proteins of
the OMM like TOM20, or at the single cell level using flow cytometry, with probes such as
mitotracker or nonyl‐acridine‐orange (NAO) that binds to mitochondrial CL (Figure 3).
Colocalization between mitochondria and autophagosomes requires a probe for each structure
and microscopic analysis. One alternative is immunofluorescence with anti LC3 antibodies
and the fixable series of mitotrackers [49]. A second alternative is transient transfection with
a plasmid for expression of GFP‐LC3 together with mitotracker. A third alternative is the use
of mono‐dancylcadaverine (with UV excitation and collecting a narrow band of blue fluores‐
cent emission) and mitotracker [50, 51]. These are just some reference alternatives and many
more can be found elsewhere [49, 50]. Some less frequently used, although more robust
alternatives in quantitative aspects, are image flow cytometry and subcellular flow cytometry
(Figure 3). The former relies on colocalization metrics derived from thousands of low
magnification images obtained in flowing cells, while the latter refers to the analysis by flow
cytometry of subcellular particles obtained from cells that have fluorescently labelled auto‐
phagosomes and mitochondria, in order to quantify those particles that have dual fluorescence
as an indicator of colocalization [52, 53]. Although assessment of LC3‐I and LC3‐II by western
blot can give a measure of bulk autophagy (which is often present in lymphoma cells), it does
not provide the confidence that mitochondria are being part of that autophagic flow. Therefore,
assessment of mitochondrial mass and colocalization is necessary. Another alternative to
derive a measure of mitophagic flow using western blot, is the use of antibodies against
mitophagy receptors such as BNIP3 or Parkin. The accumulation after the addition of flow
inhibitors can also provide a measurement of mitophagic flow. This alternative is particularly
interesting for clinical samples since no transfection is required, although caveats such as
epigenetic silencing of BNIP3 should be considered in each case. The expression of tandem
proteins combining monomeric red fluorescence protein and green fluorescence protein
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(mRFP‐GFP) facilitates the monitoring of formation and maturation of autophagosomes, and
the late stage after fusion with lysosomes. Because GFP but not mRFP fluorescence is quenched
by low pH, the autophagosomes are “green‐red” double fluorescent but autophagolysosomes
are red‐only fluorescent. This allows using the ratio single red versus double fluorescence as
an indicator of autophagic flux without the need of inhibitors [54]. This measure should be
complemented with colocalization between autophagosomes and mitochondria. A new
alternative is a similar construction that includes the coding of mitochondria targeting domain,
and allows tracking of mitophagosomes until fusion with lysosomes and a direct measurement
of mitophagic flux [55]. Each of these methods has its strengths and limitations to measure
mitophagic flux, and the use of more than one method has been widely recommended [50].
The measurement of turnover as a result of biogenesis and mitophagy has been recently
facilitated with tandem probes that exploit the spectral change of the protein DsRed1‐E5 over
time (from green to red fluorescent). This probe is called mitotimer, includes a mitochondrial
targeting sequence and its expression is under the control of doxycycline [56]
Figure 3. Fission is the first step of mitophagy.
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Gamma‐aminobutyric acid receptor‐associated protein (CCCP) is an uncoupler of OXPHOS
that causes massive depolarization and increases mtROS due to leakage of superoxide anion
from the ETC. This generalized mitochondrial damage triggers mitophagy as a compensating
response, and CCCP is thus commonly used as a positive control of bulk mitophagy. In panel
A, Burkitt´s lymphoma cells were exposed to increasing doses of CCCP and analysed by flow
cytometry. CL content was assessed by the NAO probe (x‐axis) and MMP was assessed by
tetramethylrhodamine ethyl ester (TMRE) probe (y‐axis). Although CCCP caused collapse of
MMP as evaluated at 30 min, panel B shows that by 72 h MMP was completely recovered in
cells treated with 10 and 30 µM CCCP. An evaluation of mitochondrial fission by subcellular
flow cytometry is shown in panel C. Labelled cells were ruptured and immediately run in a
flow cytometer, acquiring only particles having NAO fluorescence that corresponded to
isolated mitochondria (m) or entire cells that were not ruptured (c). Numbers indicate
percentage of mitochondria having a high SSC‐A signal. The morphological changes, caused
by massive fission of the mitochondrial network and initiation of mitophagy, correlate with an
increase of the pulse area of the side scatter light signal (SSC‐A). The fluorescence images of
matching samples of non‐ruptured NAO‐labelled cells are shown at the bottom of panel C to
illustrate the morphological counterpart of the SSC‐A signal increase.
4. Conclusion
Mitophagy is a critical mechanism in the progression of B‐cell neoplasms and other haemato‐
logical malignancies. It is also critical in drug‐resistance, particularly in advanced forms of
myeloma and high‐grade lymphomas. However, mitophagy is at the centre of an integrated
system of resistance that involves mitochondrial biogenesis, dynamics, the UPS and metabolic
reprogramming. Thus, even though mitophagy is critical, there is no single mechanism of
resistance to drug treatment of advanced forms of B‐cell neoplasms. Even though some
particular mechanisms such as UPR and ERAD may prevail at some stages (as occurs in
multiple myeloma), other mechanisms such as mitophagy, autophagy and metabolic reprog‐
ramming evolve with disease progression, and these neoplasms remain incurable. However,
when these mechanisms are considered together as a system, and its occurrence is demon‐
strated in a particular case, a combined therapy can be designed to tackle one or all of them.
For example, OXPHOS‐dependent circulating CLL cells are quite sensitive to increased
mitochondrial biogenesis and blockage of mitophagy. The more advanced forms become less
OXPHOS‐dependent, are more tolerant to increased mitochondrial biogenesis and have
increased levels of basal mitophagy. These features make these neoplasm resistant to mitocans.
In addition, a cross talk with the proteasome may compensate for blockage of mitophagy
through OMMAD, and conversely mitophagy and autophagy may compensate for defective
UPR under treatment with proteasome inhibitors. By characterizing this resistance system in
particular patients at a particular disease stage, the combination of drugs that better tackle the
biological behaviour can be defined.
Targeting Mitophagy in Combined Therapies of Haematological Malignancies
http://dx.doi.org/10.5772/63306
425
Author details
Laura I. Kornblihtt1, María C. Carreras2 and Guillermo A. Blanco3*
*Address all correspondence to: gblanco@ffyb.uba.ar
1 Department of Hematology, Hospital de Clínicas San Martín, University of Buenos Aires,
Argentina
2 Laboratory of Oxygen Metabolism, University of Buenos Aires, INIGEM‐CONICET, Ar‐
gentina
3 Laboratory of Immunotoxicology (LaITo), University of Buenos Aires, IDEHU‐CONICET,
Argentina
References
[1] Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. Cell.
2014;159:1263–76. DOI: 10.1016/j.cell.2014.11.006
[2] Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145–
59. DOI: 10.1016/j.cell.2012.02.035
[3] Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are
spared from degradation and sustain cell viability. Nature Cell Biology. 2011;13:589–
98. DOI: 10.1038/ncb2220
[4] Semenza GL. Oxygen‐dependent regulation of mitochondrial respiration by hypoxia‐
inducible factor 1. The Biochemical Journal. 2007;405:1–9. DOI: 10.1042/BJ20070389
[5] Labbe K, Murley A, Nunnari J. Determinants and functions of mitochondrial behavior.
Annual Review of Cell and Developmental Biology. 2014;30:357–91. DOI: 10.1146/
annurev‐cellbio‐101011‐155756
[6] Stotland A, Gottlieb RA. Mitochondrial quality control: easy come, easy go. Biochimica
et Biophysica Acta. 2015;1853:2802–11. DOI: 10.1016/j.bbamcr.2014.12.041
[7] Neupert W, Herrmann JM. Translocation of proteins into mitochondria. Annual Review
of Biochemistry. 2007;76:723–49. DOI: 10.1146/annurev.biochem.76.052705.163409
[8] Hoppins S, Lackner L, Nunnari J. The machines that divide and fuse mitochondria.
Annual Review of Biochemistry. 2007;76:751–80. DOI: 10.1146/annurev.biochem.
76.071905.090048
Autophagy in Current Trends in Cellular Physiology and Pathology426
[9] Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK. ER tubules
mark sites of mitochondrial division. Science. 2011;334:358–62. DOI: 10.1126/science.
1207385
[10] Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, et al. Fission and
selective fusion govern mitochondrial segregation and elimination by autophagy. The
EMBO Journal. 2008;27:433–46. DOI: 10.1038/sj.emboj.7601963
[11] Hamasaki M, Furuta N, Matsuda A, Nezu A, Yamamoto A, Fujita N, et al. Autopha‐
gosomes form at ER‐mitochondria contact sites. Nature. 2013;495:389–93. DOI:
10.1038/nature11910
[12] Chu CT, Ji J, Dagda RK, Jiang JF, Tyurina YY, Kapralov AA, et al. Cardiolipin external‐
ization to the outer mitochondrial membrane acts as an elimination signal for mitoph‐
agy in neuronal cells. Nature Cell Biology. 2013;15:1197–205. DOI: 10.1038/ncb2837
[13] Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, et al. PINK1 stabilized by
mitochondrial depolarization recruits Parkin to damaged mitochondria and activates
latent Parkin for mitophagy. The Journal of Cell Biology. 2010;189:211–21. DOI: 10.1083/
jcb.200910140
[14] Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg
did not anticipate. Cancer Cell. 2012;21:297–308. DOI: 10.1016/j.ccr.2012.02.014
[15] Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc
regulates a transcriptional program that stimulates mitochondrial glutaminolysis and
leads to glutamine addiction. Proceedings of the National Academy of Sciences of the
United States of America. 2008;105:18782–7. DOI: 10.1073/pnas.0810199105
[16] Lu P. Staging and classification of lymphoma. Seminars in Nuclear Medicine.
2005;35:160–4. DOI: 10.1053/j.semnuclmed.2005.02.002
[17] Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics
of Richter syndrome reveals disease heterogeneity and predicts survival after trans‐
formation. Blood. 2011;117:3391–401. DOI: 10.1182/blood‐2010‐09‐302174
[18] Koczula KM, Ludwig C, Hayden R, Cronin L, Pratt G, Parry H, et al. Metabolic plasticity
in CLL: adaptation to the hypoxic niche. Leukemia. 2016;30:65–73. DOI: 10.1038/leu.
2015.187
[19] Cavaliere V, Lombardo T, Costantino SN, Kornblihtt L, Alvarez EM, Blanco GA.
Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3,
autophagy, and mitochondria with low doses of valproic acid and vincristine. European
Journal of Cancer. 2014;50:3243–61. DOI: 10.1016/j.ejca.2014.09.012
[20] Neuzil J, Dong LF, Rohlena J, Truksa J, Ralph SJ. Classification of mitocans, anti‐cancer
drugs acting on mitochondria. Mitochondrion. 2013;13:199–208. DOI: 10.1016/j.mito.
2012.07.112
Targeting Mitophagy in Combined Therapies of Haematological Malignancies
http://dx.doi.org/10.5772/63306
427
[21] Lombardo T, Cavaliere V, Costantino SN, Kornblihtt L, Alvarez EM, Blanco GA.
Synergism between arsenite and proteasome inhibitor MG132 over cell death in
myeloid leukaemic cells U937 and the induction of low levels of intracellular superox‐
ide anion. Toxicology and Applied Pharmacology. 2012;258:351–66.
[22] Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW. Mitofusin 1 and
mitofusin 2 are ubiquitinated in a PINK1/parkin‐dependent manner upon induction of
mitophagy. Human Molecular Genetics. 2010;19:4861–70. DOI: 10.1093/hmg/ddq419
[23] Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, et al. PINK1 and Parkin
target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell.
2011;147:893–906. DOI: 10.1016/j.cell.2011.10.018
[24] Cunningham CN, Baughman JM, Phu L, Tea JS, Yu C, Coons M, et al. USP30 and parkin
homeostatically regulate atypical ubiquitin chains on mitochondria. Nature Cell
Biology. 2015;17:160–9. DOI: 10.1038/ncb3097
[25] Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, et al. The mitochondrial
deubiquitinase USP30 opposes parkin‐mediated mitophagy. Nature. 2014;510:370–5.
DOI: 10.1038/nature13418
[26] Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, et al. PINK1/
Parkin‐mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature Cell
Biology. 2010;12:119–31. DOI: 10.1038/ncb2012
[27] Hamacher‐Brady A, Brady NR. Mitophagy programs: mechanisms and physiological
implications of mitochondrial targeting by autophagy. Cellular and molecular life
sciences: CMLS. 2016;73:775–95. DOI: 10.1007/s00018‐015‐2087‐8
[28] Ney PA. Mitochondrial autophagy: origins, significance, and role of BNIP3 and NIX.
Biochimica et Biophysica Acta. 2015;1853:2775–83. DOI: 10.1016/j.bbamcr.2015.02.022
[29] Sandoval H, Thiagarajan P, Dasgupta SK, Schumacher A, Prchal JT, Chen M, et al.
Essential role for Nix in autophagic maturation of erythroid cells. Nature. 2008;454:232–
5. DOI: 10.1038/nature07006
[30] Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP. Disease‐causing mutations in parkin impair
mitochondrial ubiquitination, aggregation, and HDAC6‐dependent mitophagy. The
Journal of Cell Biology. 2010;189:671–9. DOI: 10.1083/jcb.201001039
[31] Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6
regulates aggresome formation and cell viability in response to misfolded protein
stress. Cell. 2003;115:727–38
[32] Wojcik C, DeMartino GN. Intracellular localization of proteasomes. The International
Journal of Biochemistry & Cell Biology. 2003;35:579–89
Autophagy in Current Trends in Cellular Physiology and Pathology428
[33] Vincenz L, Jager R, O'Dwyer M, Samali A. Endoplasmic reticulum stress and the
unfolded protein response: targeting the Achilles heel of multiple myeloma. Molecular
Cancer Therapeutics. 2013;12:831–43. DOI: 10.1158/1535‐7163.MCT‐12‐0782
[34] Hao R, Nanduri P, Rao Y, Panichelli RS, Ito A, Yoshida M, et al. Proteasomes activate
aggresome disassembly and clearance by producing unanchored ubiquitin chains.
Molecular Cell. 2013;51:819–28. DOI: 10.1016/j.molcel.2013.08.016
[35] Pellegrino MW, Nargund AM, Haynes CM. Signaling the mitochondrial unfolded
protein response. Biochimica et Biophysica Acta. 2013;1833:410–6. DOI: 10.1016/
j.bbamcr.2012.02.019
[36] Mackeh R, Perdiz D, Lorin S, Codogno P, Pous C. Autophagy and microtubules – new
story, old players. Journal of Cell Science. 2013;126:1071–80. DOI: 10.1242/jcs.115626
[37] Nakamura M, Gotoh T, Okuno Y, Tatetsu H, Sonoki T, Uneda S, et al. Activation of the
endoplasmic reticulum stress pathway is associated with survival of myeloma cells.
Leukemia & Lymphoma. 2006;47:531–9. DOI: 10.1080/10428190500312196
[38] Ria R, Todoerti K, Berardi S, Coluccia AM, De Luisi A, Mattioli M, et al. Gene expression
profiling of bone marrow endothelial cells in patients with multiple myeloma. Clinical
Cancer Research: An Official Journal of the American Association for Cancer Research.
2009;15:5369–78. DOI: 10.1158/1078‐0432.CCR‐09‐0040
[39] Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, et al. Activating oxidative phos‐
phorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib
resistance of hepatocellular carcinoma. British Journal of Cancer. 2013;108:72–81. DOI:
10.1038/bjc.2012.559
[40] Rikka S, Quinsay MN, Thomas RL, Kubli DA, Zhang X, Murphy AN, et al. Bnip3
impairs mitochondrial bioenergetics and stimulates mitochondrial turnover. Cell Death
and Differentiation. 2011;18:721–31. DOI: 10.1038/cdd.2010.146
[41] Bellot G, Garcia‐Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, et al. Hypoxia‐
induced autophagy is mediated through hypoxia‐inducible factor induction of BNIP3
and BNIP3L via their BH3 domains. Molecular and Cellular Biology. 2009;29:2570–81.
DOI: 10.1128/MCB.00166‐09
[42] Murai M, Toyota M, Suzuki H, Satoh A, Sasaki Y, Akino K, et al. Aberrant methylation
and silencing of the BNIP3 gene in colorectal and gastric cancer. Clinical Cancer
Research: An Official Journal of the American Association for Cancer Research.
2005;11:1021–7
[43] Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, et al. Genome‐wide
transcriptional response to 5‐aza‐2'‐deoxycytidine and trichostatin a in multiple
myeloma cells. Cancer Research. 2008;68:44–54. DOI: 10.1158/0008‐5472.CAN‐07‐2531
Targeting Mitophagy in Combined Therapies of Haematological Malignancies
http://dx.doi.org/10.5772/63306
429
[44] Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, et al.
Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined
by microarray analysis. Leukemia. 2009;23:2281–9. DOI: 10.1038/leu.2009.176
[45] Cowell RM, Talati P, Blake KR, Meador‐Woodruff JH, Russell JW. Identification of novel
targets for PGC‐1alpha and histone deacetylase inhibitors in neuroblastoma cells.
Biochemical and Biophysical Research Communications. 2009;379:578–82. DOI:
10.1016/j.bbrc.2008.12.109
[46] Sitarz  KS,  Elliott  HR,  Karaman  BS,  Relton  C,  Chinnery  PF,  Horvath  R.  Valproic
acid  triggers  increased  mitochondrial  biogenesis  in  POLG‐deficient  fibroblasts.
Molecular  Genetics  and  Metabolism.  2014;112:57–63.  DOI:  10.1016/j.ymgme.
2014.03.006
[47] Yoon  JY,  Ishdorj  G,  Graham  BA,  Johnston  JB,  Gibson  SB.  Valproic  acid
enhances  fludarabine‐induced  apoptosis  mediated  by  ROS  and  involving
decreased  AKT  and  ATM  activation  in  B‐cell‐lymphoid  neoplastic  cells.
Apoptosis:  An  International  Journal  on  Programmed  Cell  Death.  2014;19:191–
200.  DOI:  10.1007/s10495‐013‐0906‐7
[48] Mauro‐Lizcano M, Esteban‐Martinez L, Seco E, Serrano‐Puebla A, Garcia‐Ledo L,
Figueiredo‐Pereira C, et al. New method to assess mitophagy flux by flow cytometry.
Autophagy. 2015;11:833–43. DOI: 10.1080/15548627.2015.1034403
[49] Dolman NJ, Chambers KM, Mandavilli B, Batchelor RH, Janes MS. Tools and techniques
to measure mitophagy using fluorescence microscopy. Autophagy. 2013;9:1653–62.
DOI: 10.4161/auto.24001
[50] Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A,
et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd
edition). Autophagy. 2016;12:1–222. DOI: 10.1080/15548627.2015.1100356
[51] Iwai‐Kanai E, Yuan H, Huang C, Sayen MR, Perry‐Garza CN, Kim L, et al. A method
to measure cardiac autophagic flux in vivo. Autophagy. 2008;4:322–9
[52] de la Calle C, Joubert PE, Law HK, Hasan M, Albert ML. Simultaneous assessment of
autophagy and apoptosis using multispectral imaging cytometry. Autophagy.
2011;7:1045–51
[53] Degtyarev M, Reichelt M, Lin K. Novel quantitative autophagy analysis by organelle
flow cytometry after cell sonication. PLoS One. 2014;9:e87707. DOI: 10.1371/jour‐
nal.pone.0087707
[54] Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process
by a novel reporter protein, tandem fluorescent‐tagged LC3. Autophagy. 2007;3:452–
60
Autophagy in Current Trends in Cellular Physiology and Pathology430
[55] Kim SJ, Khan M, Quan J, Till A, Subramani S, Siddiqui A. Hepatitis B virus disrupts
mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis. PLoS
Pathogens. 2013;9:e1003722. DOI: 10.1371/journal.ppat.1003722
[56] Gottlieb RA, Stotland A. MitoTimer: a novel protein for monitoring mitochondrial
turnover in the heart. Journal of Molecular Medicine (Berl). 2015;93:271–8. DOI: 10.1007/
s00109‐014‐1230‐6
Targeting Mitophagy in Combined Therapies of Haematological Malignancies
http://dx.doi.org/10.5772/63306
431

